MedTrace Logo

Prospective Phase II Study for Assessment of Regulatory Immune Cell Populations After Allogeneic HSCT

NCT00587574 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2008-01-07

No results posted yet for this study

Summary

Allogeneic hematopoietic cell transplantation offers high cure rates for patients with hematological and oncological diseases. Graft-versus-host disease (attack of donor's white blood cells on patient's tissues) is a serious complication also affecting the patient's immune system. Therefore, patients in the early phase after allogeneic cell transplantation are at high risk for severe infectious complications. So far, no predictive biomarkers for the development of the chronic form of graft-versus-host disease are available. By analysing serially immune cell populations of the peripheral blood we will investigate whether certain subsets of cells are associated with development of chronic graft-versus-host disease. In addition, the patients' immune regeneration will be evaluated by serial analyses of peripheral blood immune cell populations 3 months to 2 years after allogeneic cell transplantation.

Conditions

  • Allogeneic Hematopoietic Cell Transplant Recipients

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Hildegard T Greinix, Professor · Medical University of Vienna

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2010-12-31
Completion
2011-12-31

Countries

  • Austria
  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00587574 on ClinicalTrials.gov